A randomized, open-label, vehicle-controlled, parallel, dose-ranging study to assess the pharmacodynamics of topically applied Imiquimod in healthy volunteers
Latest Information Update: 09 Feb 2023
At a glance
- Drugs Imiquimod (Primary) ; Imiquimod (Primary)
- Indications Actinic keratosis; Basal cell cancer; Genital warts; Herpes simplex virus infections; Squamous cell cancer; Warts
- Focus Biomarker; Pharmacodynamics
- 13 Jul 2016 Status changed from recruiting to completed.
- 12 Apr 2016 New trial record